When it comes to lario therapeutics awarded $2.4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, eDINBURGH, Scotland, Feb. 19, 2026 - Lario Therapeutics, a pioneering biopharmaceutical company focused on developing precision medicines for neurological disorders, has been awarded $2.4 million in grants from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and Wellcome. This funding aims to bolster the company's innovative neuronal calcium channel drug discovery platform, facilitating research into conditions like Parkinson's disease and post-traumatic stress disorder (PTSD).
Understanding Lario Therapeutics Awarded $2.4m By The Michael J. Fox Foundation And Wellcome To Expand Neuronal Calcium Channel Platform Across CNS Disorders
The significant $2.4 million funding, split between MJFF and Wellcome, marks a crucial milestone for Lario Therapeutics. The MJFF has committed $1.5 million to support the company's work on the CaV1.3-linked biology of Parkinson's disease, a target recognized for its relevance in disease progression. This initiative aligns with MJFF's ongoing Targets to Therapies program, which seeks to identify and prioritize promising drug targets in Parkinson's disease. Learn more about this topic on Wikipedia.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, Meanwhile, Wellcome has awarded Lario a $900,000 grant aimed at validating CaV2.3 as a target for PTSD. Recent human genetics studies have established a connection between variations in the gene encoding CaV2.3 (CACNA1E) and an increased risk of developing PTSD. By securing this funding, Lario is poised to expand its research into the therapeutic potential of selective CaV2.3 inhibitors across various central nervous system disorders.
Expanding Research into Parkinson's and PTSD
Lario's advancements in the treatment of Parkinson's disease stem from its focus on voltage-gated neuronal calcium channels. The company previously received a substantial $6 million grant from MJFF in 2024, which supported preclinical studies on CaV2.3. These efforts aim not only to explore the therapeutic potential of CaV2.3 in Parkinson's but also to extend its applications to other neurological conditions.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, Henning Steinhagen, CEO of Lario Therapeutics, expressed gratitude for the continued backing from MJFF and Wellcome, stating, "Lario was founded to translate strong human genetics and neuronal biology into precision medicines for patients with severe neurological disease." He emphasized that this funding will enable the company to advance its unique programs closer to clinical application, addressing the substantial unmet needs of patients.
Recognition from Leading Organizations
The dual support from MJFF and Wellcome serves as a validation of Lario's cutting-edge research and innovative approach to drug discovery. Tom Otis, Chief Scientific Officer at Lario, noted, "These awards recognize the growing body of evidence linking neuronal calcium channel dysfunction to the core biology of neurological and psychiatric diseases." This acknowledgment from respected institutions underscores the significance of Lario's work in the field.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, Lario's approach combines selective small-molecule chemistry with rigorous target biology, aiming to create a unique platform designed to offer new therapeutic options for patients suffering from debilitating neurological conditions. By focusing on neuronal calcium channels, Lario is tackling fundamental mechanisms underlying various disorders, potentially leading to effective treatment solutions.
Future Directions for Lario Therapeutics
With this new influx of funding, Lario Therapeutics plans to accelerate its research efforts and expand the scope of its projects. By further investigating the roles of CaV1.3 and CaV2.3 in neurological disorders, the company aims to pave the way for innovative treatments that could significantly improve patient outcomes.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, The grants signify more than just financial support; they represent a commitment to advancing scientific discovery in the realm of neurological and psychiatric health. As Lario moves forward, the implications of its research could resonate across a range of conditions, offering hope to those affected by diseases that currently lack effective treatments.
Regarding lario therapeutics awarded .4m by the michael j. fox foundation and wellcome to expand neuronal calcium channel platform across cns disorders, So, Lario Therapeutics stands at a pivotal moment in its development, equipped with substantial funding from notable organizations. The company's focus on precision medicine and innovative drug discovery could not only reshape treatment paradigms for Parkinson's disease and PTSD but also contribute to a broader understanding of neuronal health.